Disease on EC 3.2.2.8 - ribosylpyrimidine nucleosidase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE 
TITLE OF PUBLICATION
LINK TO PUBMED
Acanthamoeba Keratitis
Production of a polyclonal antibody against inosine-uridine preferring nucleoside hydrolase of Acanthamoeba castellanii and its access to diagnosis of Acanthamoeba keratitis.
Anthrax
Analysis of Bacillus anthracis nucleoside hydrolase via in silico docking with inhibitors and molecular dynamics simulation.
Anthrax
Combined virtual screening, MMPBSA, molecular docking and dynamics studies against deadly anthrax: An in silico effort to inhibit Bacillus anthracis nucleoside hydrolase.
Anthrax
Design of new chemotherapeutics against the deadly anthrax disease. Docking and molecular dynamics studies of inhibitors containing pyrrolidine and riboamidrazone rings on nucleoside hydrolase from Bacillus anthracis.
Bacterial Infections
Analysis of Bacillus anthracis nucleoside hydrolase via in silico docking with inhibitors and molecular dynamics simulation.
Infections
A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection.
Infections
Druggability of the guanosine/adenosine/cytidine nucleoside hydrolase from Trichomonas vaginalis.
Infections
Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Infections
Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.
Infections
The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice.
Leishmaniasis
F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.
Leishmaniasis, Cutaneous
Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasis.
Leishmaniasis, Cutaneous
Isoenzyme characterization of Leishmania isolated from human cases with localized cutaneous leishmaniasis from the State of Campeche, Yucatan Peninsula, Mexico.
Leishmaniasis, Visceral
Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
Leishmaniasis, Visceral
Expression, purification and spectrophotometric analysis of nucleoside hydrolase from Leishmania chagasi (LcNH).
Leishmaniasis, Visceral
F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.
Leishmaniasis, Visceral
Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis.
Leishmaniasis, Visceral
Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis.
Neoplasms
Crystal structure to 1.7 a of the Escherichia coli pyrimidine nucleoside hydrolase YeiK, a novel candidate for cancer gene therapy.
Neoplasms
Identification of a 2'-O-Methyluridine Nucleoside Hydrolase Using the Metagenomic Libraries.
Parasitic Diseases
Analysis of Bacillus anthracis nucleoside hydrolase via in silico docking with inhibitors and molecular dynamics simulation.
Trypanosomiasis, African
Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
Tuberculosis
Biochemical characterization of recombinant nucleoside hydrolase from Mycobacterium tuberculosis H37Rv.
html completed
